Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 23, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("GSK Trust"). On January 21, 2004, Abacus (GSK) Trustees Limited transferred 17,426 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on January 22, 2004.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Checklist
- Verify the total number of shares transferred (17,426) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the identities of the directors with interests in the GSK Trust (Dr. J-P Garnier, Dr. T Yamada, Mr. J D Coombe).
- Note that this filing contains no financial performance data; refer to Form 20-F for comprehensive financial results.